Severe Infection of Pseudomonas aeruginosa during Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria

Eculizumab is the complement inhibitor administered to ameliorate intravascular hemolysis in paroxysmal nocturnal hemoglobinuria. Whether or not the inhibitory mechanism may also increase the susceptibility to non-Neisserial infection is unclear. A 73-year old woman presented with bacteremia, cholec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawakami, Toru, Nakazawa, Hideyuki, Kurasawa, Yukifumi, Sakai, Hitoshi, Nishina, Sayaka, Senoo, Noriko, Senoo, Yasushi, Ishida, Fumihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799070/
https://www.ncbi.nlm.nih.gov/pubmed/29021487
http://dx.doi.org/10.2169/internalmedicine.9151-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799070/
https://www.ncbi.nlm.nih.gov/pubmed/29021487
http://dx.doi.org/10.2169/internalmedicine.9151-17

Ejemplares similares